Kalaris Therapeutics (KLRS) Misses Q2 EPS by 61c

Kalaris Therapeutics (NASDAQ: KLRS) reported Q2 EPS of ($0.61).

For earnings history and earnings-related data on Kalaris Therapeutics (KLRS) click here.

You May Also Be Interested In

• Bessent: We Make A Market Buying Older Bonds
• Activist investor presses Xerox to review financial services arm - Bloomberg
• Tenable to integrate Anthropic's Claude into its security platform